A GLP-1 study in Philadelphia will test effectiveness against alcohol use disorder

Key Points:

• A Philadelphia VA doctor is leading a national trial testing GLP-1 drugs, typically used for diabetes and weight loss, to treat alcohol use disorder (AUD) in 622 veterans across 18 VA sites.
• GLP-1 drugs mimic a natural hormone affecting brain receptors linked to reward, potentially reducing cravings for alcohol without diminishing pleasure, with the trial designed to meet FDA requirements including a six-month treatment period.
• Recruitment begins this week, with participants randomly assigned to receive either the drug or a placebo, and results expected in about three years; the study aims to improve treatment uptake, as fewer than 10% of people with AUD currently receive any treatment annually.
• Early small trials suggest GLP-1s may be more effective than current AUD medications, and because primary care providers are already comfortable prescribing GLP-1s for other conditions, these drugs could become a widely accessible front-line treatment if proven safe and effective.
• The trial emphasizes safety and efficacy, discouraging unsupervised use of GLP-1s for AUD, and highlights that veterans seeking help can contact the Veterans Crisis Line for support regardless of enrollment in the study.